China · Delayed Price · Currency is CNY GemPharmatech Statistics
Total Valuation
GemPharmatech has a market cap or net worth of CNY 7.51 billion. The enterprise value is 6.54 billion.
| Market Cap | 7.51B |
| Enterprise Value | 6.54B |
Important Dates
The last earnings date was Saturday, August 23, 2025.
| Earnings Date | Aug 23, 2025 |
| Ex-Dividend Date | Jul 11, 2025 |
Share Statistics
GemPharmatech has 408.99 million shares outstanding. The number of shares has increased by 2.51% in one year.
| Current Share Class | 408.99M |
| Shares Outstanding | 408.99M |
| Shares Change (YoY) | +2.51% |
| Shares Change (QoQ) | -5.23% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 17.23% |
| Float | 160.79M |
Valuation Ratios
The trailing PE ratio is 72.89 and the forward PE ratio is 45.90.
| PE Ratio | 72.89 |
| Forward PE | 45.90 |
| PS Ratio | 10.41 |
| PB Ratio | 3.46 |
| P/TBV Ratio | 3.54 |
| P/FCF Ratio | 200.70 |
| P/OCF Ratio | 50.35 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 37.32, with an EV/FCF ratio of 174.78.
| EV / Earnings | 62.64 |
| EV / Sales | 9.07 |
| EV / EBITDA | 37.32 |
| EV / EBIT | 71.88 |
| EV / FCF | 174.78 |
Financial Position
The company has a current ratio of 3.28, with a Debt / Equity ratio of 0.14.
| Current Ratio | 3.28 |
| Quick Ratio | 3.13 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 1.77 |
| Debt / FCF | 8.28 |
| Interest Coverage | 18.42 |
Financial Efficiency
Return on equity (ROE) is 4.88% and return on invested capital (ROIC) is 2.40%.
| Return on Equity (ROE) | 4.88% |
| Return on Assets (ROA) | 2.10% |
| Return on Invested Capital (ROIC) | 2.40% |
| Return on Capital Employed (ROCE) | 4.03% |
| Revenue Per Employee | 457,074 |
| Profits Per Employee | 66,152 |
| Employee Count | 1,578 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 4.72 |
Taxes
In the past 12 months, GemPharmatech has paid 14.86 million in taxes.
| Income Tax | 14.86M |
| Effective Tax Rate | 12.46% |
Stock Price Statistics
The stock price has increased by +71.96% in the last 52 weeks. The beta is 0.61, so GemPharmatech's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | +71.96% |
| 50-Day Moving Average | 16.75 |
| 200-Day Moving Average | 14.23 |
| Relative Strength Index (RSI) | 56.33 |
| Average Volume (20 Days) | 5,212,205 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GemPharmatech had revenue of CNY 721.26 million and earned 104.39 million in profits. Earnings per share was 0.25.
| Revenue | 721.26M |
| Gross Profit | 447.02M |
| Operating Income | 90.97M |
| Pretax Income | 119.25M |
| Net Income | 104.39M |
| EBITDA | 163.61M |
| EBIT | 90.97M |
| Earnings Per Share (EPS) | 0.25 |
Balance Sheet
The company has 1.28 billion in cash and 309.81 million in debt, giving a net cash position of 969.88 million or 2.37 per share.
| Cash & Cash Equivalents | 1.28B |
| Total Debt | 309.81M |
| Net Cash | 969.88M |
| Net Cash Per Share | 2.37 |
| Equity (Book Value) | 2.17B |
| Book Value Per Share | 5.30 |
| Working Capital | 1.24B |
Cash Flow
In the last 12 months, operating cash flow was 149.14 million and capital expenditures -111.73 million, giving a free cash flow of 37.41 million.
| Operating Cash Flow | 149.14M |
| Capital Expenditures | -111.73M |
| Free Cash Flow | 37.41M |
| FCF Per Share | 0.09 |
Margins
Gross margin is 61.98%, with operating and profit margins of 12.61% and 14.47%.
| Gross Margin | 61.98% |
| Operating Margin | 12.61% |
| Pretax Margin | 16.53% |
| Profit Margin | 14.47% |
| EBITDA Margin | 22.68% |
| EBIT Margin | 12.61% |
| FCF Margin | 5.19% |
Dividends & Yields
This stock pays an annual dividend of 0.14, which amounts to a dividend yield of 0.74%.
| Dividend Per Share | 0.14 |
| Dividend Yield | 0.74% |
| Dividend Growth (YoY) | -12.50% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 77.49% |
| Buyback Yield | -2.51% |
| Shareholder Yield | -1.78% |
| Earnings Yield | 1.39% |
| FCF Yield | 0.50% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GemPharmatech has an Altman Z-Score of 6.08 and a Piotroski F-Score of 5.
| Altman Z-Score | 6.08 |
| Piotroski F-Score | 5 |